Factors associated with statin discontinuation near end of life in a Danish primary health care cohort. (11th August 2022)

• Record Type: Journal Article
• Authors: Engell, Anna E; Bathum, Lise; Andersen, John S; Thompson, Wade; Lind, Bent S; Jørgensen, Henrik L; Nexøe, Jørgen
• Is Part Of: Family practice. Volume 40:Number 2(2023)
• Page Start: 300
• Page End: 307
• Publication Date: 2022-08-11
• Subjects: discontinuation of medication -- end of life care -- general practice -- statins; Primary care (Medicine) -- Periodicals; Clinical medicine -- Periodicals; 616.005
• DOI: 10.1093/fampra/cmac090
• Languages: English
• ISSNs: 0263-2136

Abstract

Abstract: Background: Long-term preventive treatment such as treatment with statins should be reassessed among patients approaching end of life. The aim of the study was to describe the rate of discontinuation of statin treatment and factors associated with discontinuation in the 6 months before death. Methods: This study is a retrospective cohort study using national registers and blood test results from primary health care patients. Patients in the Copenhagen municipality, Denmark who died between 1997 and 2018 and were statin users during the 10-year period before death were included. We calculated the proportion who remained statin users in the 6-month period before death. Factors associated with discontinuation were tested using logistic regression. Results: A total of 55, 591 decedents were included. More patients continued treatment (64%, n = 35, 693) than discontinued (36%, n = 19, 898) the last 6 months of life. The 70 and 80 age groups had the lowest odds of discontinuing compared to the 90 (OR 1.59, 95% CI 0.93–2.72) and 100 (OR 3.11, 95% CI 2.79–3.47) age groups. Increasing comorbidity score (OR 0.89, 95% CI 0.87; 0.90 per 1-point increase) and use of statins for secondary prevention (OR 0.89, 95% CI 0.85; 0.93) reduced the likelihood of discontinuation as did a diagnosis of dementia, heart failure, or cancer. Conclusion: A substantial portion of patients continued statin treatment near end of life. Efforts to promote rational statin use and discontinuation are required among patients with limited life expectancy, including establishing clear, practical recommendations about statin discontinuation, and initiatives to translate recommendations into clinical practice.